GLP-3 (R) 30mg

GLP‑3 (R) – 30mg

Triple‑Agonist Metabolic Peptide • Lyophilized Powder • Research Use Only

Description: GLP‑3 (R) is an investigational triple‑agonist peptide engineered to activate three major metabolic receptors simultaneously: GLP‑1, GIP, and glucagon. This multi‑pathway engagement produces some of the most profound metabolic effects observed in peptide research, including significant weight reduction, enhanced glycemic control, and increased energy expenditure.

Triple‑agonist compounds like GLP‑3 (R) have demonstrated metabolic outcomes that surpass single‑ or dual‑agonist analogs, making them a leading focus in advanced obesity and diabetes research.

Specifications

• Peptide: GLP‑3 (R)

• Classification: Triple‑Receptor Agonist (GLP‑1 / GIP / Glucagon)

• Quantity: 30mg per vial

• Purity: ≥99.8%

• Form: Lyophilized powder

• Physical Description: White to off‑white lyophilized powder

• Solubility: Soluble in aqueous diluents

• Storage:

  • Store at −20°C (−4°F)

  • Protect from moisture and prolonged light exposure

  • After reconstitution, refrigerate at 2–8°C (36–46°F); use within 30 days

• Grade: Research Use Only — Not for human consumption, therapeutic, or diagnostic use

Key Research Insights

• Unprecedented Weight Loss GLP‑3 (R) has demonstrated average weight reductions of up to 24% after 48 weeks in advanced research models—approaching bariatric‑level outcomes.

• Targeted Fat Reduction Studies show significant decreases in visceral fat (organ fat) and subcutaneous abdominal fat, indicating deep metabolic remodeling.

• Increased Calorie Burning The glucagon‑agonist component elevates energy expenditure, enhancing natural fat oxidation beyond what GLP‑1 or GIP alone can achieve.

• Blood Sugar & Insulin Control GLP‑3 (R) has been shown to reduce HbA1c, improve insulin sensitivity, and support remission‑level improvements in pre‑diabetes and type 2 diabetes models.

• Cardiometabolic Health Early research indicates improvements in blood pressure, triglycerides, and liver steatosis, suggesting broad systemic benefits.

Mechanistic Interest — How GLP‑3 (R) Works

GLP‑3 (R) mimics and amplifies the actions of three endogenous metabolic hormones:

• GLP‑1: Slows gastric emptying and reduces appetite through central satiety pathways.

• GIP: Enhances insulin secretion and improves lipid metabolism.

• Glucagon: Increases energy expenditure and stimulates fat oxidation, driving additional calorie burn.

This triple‑pathway synergy produces metabolic effects far exceeding those of single‑ or dual‑agonist peptides, making GLP‑3 (R) a leading compound in next‑generation obesity, diabetes, and cardiometabolic research.

Research Focus Areas

• Triple‑agonist metabolic pathway studies

• Body‑weight reduction and adiposity‑modulation models

• Glycemic control and HbA1c‑lowering research

• Energy‑expenditure and fat‑oxidation mechanisms

• Cardiometabolic health and lipid‑profile investigations

• Obesity, pre‑diabetes, and T2DM research